Announces

Alto Neuroscience Announces Additional Funding of $60 Million

– New investor Alpha Wave Ventures has invested $25 million as part of Series B, extending the operating runway until 2025. – – Alto entered into a $35 million credit facility with K2 HealthVentures – – The company is now funded through four placebo-controlled phase 2 studies with four different product candidates for three different …

Alto Neuroscience Announces Additional Funding of $60 Million Read More »

Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy | DNA, RNA and cells

Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy details Category: DNA RNA and cells Posted on Saturday, January 28, 2023 at 6:33 pm Visit: 132 The START-001 study uses a tissue-agnostic biomarker-enriched approach to evaluate …

Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy | DNA, RNA and cells Read More »

REGENXBIO Announces Phase I/II Trial of RGX-202, Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, Is Active and Recruiting Patients

– The company launched Phase I/II AFFINITY DUCHENNE™ testing RGX-202 – The company is also including a new active observational screening study, AFFINITY BEYOND, evaluating the prevalence of AAV8 antibodies in boys with Duchenne – Commercial cGMP material from REGENXBIO Manufacturing Innovation Center to be used in clinical trial – RGX-202 is a potential single-agent …

REGENXBIO Announces Phase I/II Trial of RGX-202, Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, Is Active and Recruiting Patients Read More »

bioAffinity Technologies announces the grant of US patents protecting novel compounds for the specific delivery of cancer treatment

SAN ANTONIO–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced today that the US Patent and Trademark Office (USPTO) has granted a Notice of Allowance for a patent application entitled “Porphyrin compounds and compositions useful for the treatment of cancer” for the targeted delivery of new cancer drugs. A Notice of Allowance is issued after the …

bioAffinity Technologies announces the grant of US patents protecting novel compounds for the specific delivery of cancer treatment Read More »

Crypto exchange Unicoin announces cooperation with crypto tax partner Binocs

On Monday, India’s first cryptocurrency exchange Unicoin announced a partnership with Binocs, a cryptocurrency tax company, as a tax partner. According to a press release sent by Unicoin, “The collaboration will enable Unocoin users and all Indian cryptocurrency enthusiasts to easily calculate their crypto taxes by embedding their accounts with Binocs.” It will also help …

Crypto exchange Unicoin announces cooperation with crypto tax partner Binocs Read More »

Biomind Labs Announces Completion of First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer’s Disease

TORONTO, December 28, 2022—(BUSINESS WIRE)–Biomind Labs Inc. (“Biomind Labs” or “Society“) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotechnology company focused on developing the next generation of medicines to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the healing power of psychedelic molecules, is pleased to announce that successfully completed the …

Biomind Labs Announces Completion of First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer’s Disease Read More »

PeptiDream announces a new research and collaboration agreement with Lilly for the discovery of novel peptide drug conjugates

KANAGAWA, Japan–(BUSINESS WIRE)–PeptiDream Inc., a publicly traded biopharmaceutical company headquartered in Kanagawa, Japan (Chairman: Patrick C. Reid, “PeptiDream”) (Tokyo: 4587) today announced that it has entered into a Research Collaboration and License Agreement with the US – based at Eli Lilly and Company (Lilly) focused on the discovery and development of new peptide drug conjugates …

PeptiDream announces a new research and collaboration agreement with Lilly for the discovery of novel peptide drug conjugates Read More »

ObsEva announces the rejection of moratorium procedures

Ad hoc publication based on Art. 53 LR of the Swiss Stock Exchange SIX GENEVA, Switzerland– December 19in 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company that develops and commercializes new therapies for women’s health, announced today that the competent court in Geneva, Switzerland approved the Company’s request to lift the moratorium, …

ObsEva announces the rejection of moratorium procedures Read More »

Abata Therapeutics Announces First Lead in Development, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis

BOSTON–(BUSINESS WIRE)–Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that it has selected its first development candidate, ABA-101, which has the potential to benefit the 45,000 patients with progressive multiple sclerosis (MS) in the US …

Abata Therapeutics Announces First Lead in Development, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis Read More »